{'52WeekChange': 0.5508772,
 'SandP52WeekChange': None,
 'address1': '200 Sidney Street',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.34,
 'askSize': 1000,
 'averageDailyVolume10Day': 782200,
 'averageVolume': 661739,
 'averageVolume10days': 782200,
 'beta': 1.118767,
 'beta3Year': None,
 'bid': 4.11,
 'bidSize': 1400,
 'bookValue': -0.86,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.36,
 'dayLow': 4.02,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.468,
 'enterpriseToRevenue': 7.531,
 'enterpriseValue': 266383328,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.736143,
 'fiftyTwoWeekHigh': 6.75,
 'fiftyTwoWeekLow': 2.15,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43603021,
 'forwardEps': -1.02,
 'forwardPE': -4.019608,
 'fromCurrency': None,
 'fullTimeEmployees': 108,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.10002,
 'heldPercentInstitutions': 0.80148005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/serestherapeutics.com',
 'longBusinessSummary': 'Seres Therapeutics, Inc., a microbiome therapeutics '
                        'platform company, engages in developing biological '
                        'drugs that are designed to treat disease by restoring '
                        "the function of a dysbiotic microbiome. The company's "
                        'advanced program is the SER-109, which is in Phase '
                        'III clinical development for reducing recurrent '
                        'clostridium difficile infection (CDI). It is also '
                        'developing SER-287 that is in Phase IIb study in '
                        'patients with active mild-to-moderate ulcerative '
                        'colitis; and SER-401, which is in Phase Ib study in '
                        'metastatic melanoma to augment the efficacy of '
                        'anti-PD-1 immunotherapy. In addition, the company '
                        'engages in the development of SER-301, an Ecobiotic '
                        'microbiome therapeutic candidate for the treatment of '
                        'inflammatory bowel disease; and SER-109, a '
                        'donor-derived purified bacterial spore-based '
                        'microbiome therapeutic candidate that is in Phase III '
                        'clinical trial to correct dysbiosis in the colonic '
                        'microbiome in the setting of recurrent CDI. Further, '
                        'it is developing SER-262, a multi-strain Ecobiotic '
                        'microbiome therapeutic candidate, which is in Phase '
                        'Ib study for CDI antibiotic treatment; and SER-155, a '
                        'microbiome therapeutic candidate to correct dysbiosis '
                        'in patients following allogeneic hematopoietic stem '
                        'cell or solid organ transplants. The company has '
                        'license and collaboration agreement with Nestec Ltd. '
                        'and Memorial Sloan Kettering Cancer Center, as well '
                        'as collaboration with AstraZeneca. The company was '
                        'formerly known as Seres Health, Inc. and changed its '
                        'name to Seres Therapeutics, Inc. in May 2015. Seres '
                        'Therapeutics, Inc. was founded in 2010 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Seres Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 297656320,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_222388947',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -65827000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.36,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.03,
 'phone': '617 945 9626',
 'previousClose': 4.42,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 8.414788,
 'profitMargins': -1.86094,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.36,
 'regularMarketDayLow': 4.02,
 'regularMarketOpen': 4.36,
 'regularMarketPreviousClose': 4.42,
 'regularMarketPrice': 4.36,
 'regularMarketVolume': 727767,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 72599104,
 'sharesPercentSharesOut': 0.1025,
 'sharesShort': 7439703,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6735924,
 'shortName': 'Seres Therapeutics, Inc.',
 'shortPercentOfFloat': 0.21219999,
 'shortRatio': 12.32,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'MCRB',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.027,
 'twoHundredDayAverage': 3.997338,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '142fe857-307b-3629-9b7d-860e8fe50185',
 'volume': 727767,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.serestherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}